Developing novel therapeutic approaches to frailty.
Frailty is now defined as a clinical entity and potentially responsive to medications. This article reviews the drugs available and those under development. While, at present, exercise is the primary therapy, it is expected over the next decade that numerous drugs will be available to treat components of the frailty syndrome.
Morley
John E
JE
Division of Geriatric Medicine, Saint Louis University School of Medicine and GRECC, VA Medical Center, St. Louis, Missouri 63104, USA. morley@slu.edu
D000368:Aged / Q000502:physiology*; D000375:Aging / Q000502:physiology*; D045930:Anabolic Agents / Q000494:pharmacology; D000740:Anemia / Q000503:physiopathology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000855:Anorexia / Q000503:physiopathology; D050197:Atherosclerosis / Q000097:blood; D016207:Cytokines / Q000502:physiology; D056344:Executive Function / Q000502:physiology; D005221:Fatigue / Q000503:physiopathology; D005395:Fish Oils / Q000494:pharmacology; D016330:Frail Elderly; D019382:Human Growth Hormone / Q000494:pharmacology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008931:Mitochondria, Muscle / Q000502:physiology; D009046:Motor Neurons / Q000502:physiology; D018485:Muscle Fibers, Skeletal / Q000502:physiology; D018482:Muscle, Skeletal / Q000473:pathology; D055435:Myostatin / Q000494:pharmacology; D014807:Vitamin D / Q000494:pharmacology
D045930:Anabolic Agents; D000806:Angiotensin-Converting Enzyme Inhibitors; D016207:Cytokines; D005395:Fish Oils; D055435:Myostatin; D019382:Human Growth Hormone; D014807:Vitamin D